Jupiter Neurosciences (NASDAQ:JUNS – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.
Volatility & Risk
Jupiter Neurosciences has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500. Comparatively, Silo Pharma has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.
Insider and Institutional Ownership
5.6% of Silo Pharma shares are held by institutional investors. 38.6% of Jupiter Neurosciences shares are held by insiders. Comparatively, 3.6% of Silo Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jupiter Neurosciences | 1 | 0 | 0 | 0 | 1.00 |
| Silo Pharma | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares Jupiter Neurosciences and Silo Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Jupiter Neurosciences | N/A | N/A | -246.66% |
| Silo Pharma | -6,726.39% | -81.75% | -66.35% |
Valuation & Earnings
This table compares Jupiter Neurosciences and Silo Pharma”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Jupiter Neurosciences | $20,000.00 | 101.01 | -$8.65 million | ($19.12) | -0.12 |
| Silo Pharma | $70,000.00 | 40.66 | -$4.23 million | ($4.36) | -0.41 |
Silo Pharma has higher revenue and earnings than Jupiter Neurosciences. Silo Pharma is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Jupiter Neurosciences beats Silo Pharma on 6 of the 11 factors compared between the two stocks.
About Jupiter Neurosciences
Jupiter Neurosciences, Inc. (NASDAQ:JUNS) is a clinical-stage biotechnology company focused on developing therapies for diseases associated with neuroinflammation. The company’s research is centered on small-molecule drug candidates intended to address inflammatory processes affecting the central nervous system. Jupiter Neurosciences’ lead product candidate, JNS-101, is an orally administered, brain-penetrant compound being developed for its potential anti-inflammatory and neuroprotective effects.
About Silo Pharma
Silo Pharma, Inc. is a development-stage biopharmaceutical company focused on developing therapeutics that combine traditional pharmaceutical approaches with psychedelic research. The company’s programs are intended to address conditions involving pain, inflammation, neurological disorders, and mental health. Silo Pharma’s pipeline has included SP-26, an investigational ketamine-based implant designed to provide sustained drug delivery and being explored for conditions such as fibromyalgia. Its research portfolio has also included intranasal formulations and other therapeutics targeting disorders such as post-traumatic stress disorder and Alzheimer’s disease.
Receive News & Ratings for Jupiter Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jupiter Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
